Ventolin Tablets (Salbutamol 2mg/4mg)

Medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist — Updated April 2026

What Are Ventolin Tablets (Oral Salbutamol)? — Mechanism and Pharmacology

Salbutamol is a selective beta-2 adrenergic agonist — it binds to beta-2 receptors on bronchial smooth muscle, activating the adenylyl cyclase → cyclic AMP → protein kinase A cascade that ultimately causes smooth muscle relaxation and bronchodilation. The active molecule is identical to the salbutamol in the Ventolin inhaler; the critical difference is the route of administration and its pharmacokinetic consequences.

Oral vs inhaled salbutamol — pharmacokinetic comparison:

Why Oral Salbutamol Tablets? — Canadian Clinical Indications

Canadian asthma management guidelines (CTS, GINA) unambiguously prefer the inhaled route for salbutamol delivery in virtually all situations. Oral salbutamol tablets have specific, narrower clinical indications in Canadian practice:

1. Young children unable to use inhaled therapy effectively: The primary Canadian indication for oral salbutamol. Correct inhaler technique requires coordination between actuation and inhalation that very young children (typically under 3–4 years) cannot reliably perform — even with a face-mask spacer device. In young children with frequent asthma symptoms or recurrent wheeze who cannot use a spacer/mask device effectively, oral salbutamol syrup (liquid formulation, which may be preferred over tablets in very young children) or tablets (for older toddlers who can swallow) provides systemic bronchodilation without requiring inhalation technique. Canadian paediatricians may prescribe oral salbutamol for young children with significant wheeze pending assessment for formal asthma diagnosis and age-appropriate inhaler training.

2. Patients unable to use any inhaler device: Certain patients with severe arthritis (affecting hand grip and coordination), severe neurological conditions affecting coordination, or severe cognitive impairment affecting device use may be candidates for oral bronchodilator therapy when other device options (dry powder inhalers, soft mist inhalers, nebulisers) have been exhausted or are not feasible.

3. Nebuliser therapy when only tablets are available: In some Canadian home nebuliser setups and specific clinical contexts, oral salbutamol tablets may be used as a systemic bronchodilator adjunct when the primary nebulised bronchodilator is unavailable.

4. Nocturnal asthma — sustained bronchodilation: In some patients with troublesome nocturnal asthma symptoms despite inhaled controller therapy, oral salbutamol tablets taken at bedtime can provide extended systemic bronchodilation through the night — though sustained-release oral bronchodilator formulations are more commonly used for this purpose in Canadian practice today.

5. COPD — systemic bronchodilation in select patients: In COPD patients with severe airflow limitation who have difficulty using inhaled devices, oral salbutamol may provide some symptomatic bronchodilation, though LAMAs and LABAs by inhaler remain the preferred controller medications in Canadian COPD management.

Health Canada-Approved Indications

• Relief and prevention of bronchospasm in patients with reversible obstructive airways disease, including asthma
• Acute episodes of bronchospasm
• Prevention of exercise-induced asthma (when inhaler is not appropriate)
• Bronchospasm associated with chronic bronchitis and emphysema (COPD)

Canadian Dosing Protocol — Oral Salbutamol Tablets

Important note on oral vs inhaled dosing: The dosing information below applies specifically to Ventolin Tablets (oral). It is completely different from the dosing for Ventolin Inhaler (which is measured in puffs of 100mcg each). Do not apply inhaler dosing information to tablet use or vice versa.

Adults and adolescents (12 years and older):

• Starting dose: 2mg to 4mg three to four times daily (every 6 to 8 hours)
• Maximum dose: 4mg four times daily (16mg/day total) for most adults
• Elderly patients and those with hyperthyroidism, cardiovascular disease, or diabetes: Start at 2mg three times daily and increase cautiously — these patients are more susceptible to cardiovascular and metabolic side effects of systemic beta-2 agonism
• If adequate response is not achieved with 4mg four times daily, do not increase further without specialist review

Children 6 to 11 years:

• 2mg three to four times daily
• Maximum: 2mg four times daily (8mg/day)

Children 2 to 5 years:

• 1mg to 2mg three times daily (liquid/syrup formulation preferred for this age group)
• For tablet use in this age group: 1mg (half of a 2mg tablet) to 2mg three times daily under physician supervision

Children under 2 years: Not recommended without specialist paediatric supervision. Inhaled therapy via spacer with face mask is strongly preferred for this age group in Canadian practice.

Taking Ventolin tablets: Swallow whole with a glass of water. Can be taken with or without food — taking with food slightly reduces nausea. If taking three times daily, space doses approximately evenly through the day (e.g., 8am, 2pm, 8pm). If taking four times daily, approximately every 6 hours.

Missed dose: Take as soon as remembered unless it is almost time for the next dose. Never double up. Continue on the regular schedule.

Side Effects — Oral Salbutamol Tablets

Because oral salbutamol produces substantially higher systemic drug concentrations than inhaled salbutamol at equivalent bronchodilator doses, side effects are generally more pronounced with tablets than with the inhaler. Patients switching from inhaler to tablets — or starting tablets for the first time — should be aware of these differences.

Very common — affecting the majority of tablet users:

• Tremor (fine muscle tremor): The most common and characteristic oral salbutamol side effect — significantly more pronounced than with the inhaler. Systemic beta-2 activation in skeletal muscle throughout the body causes fine tremor, particularly noticeable in the hands. Usually most marked in the first 1 to 2 weeks and diminishes as the body acclimatises to the medication. Does not indicate harm but can be functionally disruptive. If severe: discuss dose reduction with your physician
• Tachycardia (rapid heart rate): More pronounced than with inhaled therapy. Reflex tachycardia from systemic beta-2-mediated peripheral vasodilation plus direct beta-1 adrenergic cardiac stimulation. Typically 10–30 extra beats per minute above baseline. Clinically significant monitoring is required in patients with pre-existing cardiac conditions
• Headache: Common, particularly when starting therapy or after dose increases. Usually mild and self-limiting
• Nervous tension and restlessness: Central and peripheral nervous system stimulation produces a feeling of nervousness, jitteriness, or inner tension. More pronounced than with inhaled therapy. Usually diminishes after the first 1 to 2 weeks
• Palpitations: Awareness of heartbeat, sometimes described as a pounding sensation. Related to the tachycardia effect. Benign in most patients but should be reported to a physician if persistent or severe

Common — affecting a notable proportion of patients:

• Nausea — take tablets with food to reduce
• Dizziness — particularly on standing; rise slowly, especially in the first weeks of therapy
• Muscle cramps — due to systemic beta-2 effects on muscle metabolism
• Peripheral vasodilation — warm skin, flushing, particularly in the hands and feet

Important metabolic effect — hypokalaemia (low blood potassium):

Oral salbutamol at therapeutic doses can cause a clinically meaningful decrease in serum potassium (hypokalaemia) through beta-2-mediated stimulation of cellular potassium uptake. This effect is dose-dependent and more clinically significant with oral tablets than with standard inhaled doses. Hypokalaemia can cause muscle weakness, cramping, cardiac arrhythmias, and potentiation of digoxin toxicity.

Hypokalaemia is particularly important in:

• Patients also taking diuretics (particularly thiazides — hydrochlorothiazide — and loop diuretics — furosemide/Lasix) — these further deplete potassium, creating additive hypokalaemia risk
• Patients taking digoxin — hypokalaemia increases digoxin toxicity risk significantly
• Patients with acute severe asthma receiving high-dose salbutamol in hospital
• Patients with diabetes — salbutamol can also affect blood glucose

Serum potassium monitoring is recommended for Canadian patients on oral salbutamol tablets who are also taking diuretics or digoxin, or who have pre-existing cardiac conditions.

Cardiovascular precautions — important for specific Canadian patient populations:

Oral salbutamol should be used with caution in patients with:

• Ischaemic heart disease, hypertension, or heart failure — increased heart rate and blood pressure effects are more clinically relevant
• Hyperthyroidism — already elevated sympathetic tone; salbutamol may cause pronounced tachycardia
• Diabetes mellitus — salbutamol can cause blood glucose elevation and may affect insulin requirements
• Pre-existing cardiac arrhythmias — particularly atrial fibrillation or other tachyarrhythmias
• Hypertrophic obstructive cardiomyopathy — beta-agonists can worsen outflow tract obstruction

Seek immediate medical attention if:

• Chest pain or significant chest tightness occurs after taking a tablet
• Severe irregular heartbeat or significant palpitations
• Significant worsening of breathing after taking the tablet (paradoxical bronchospasm — rare)
• Signs of allergic reaction: skin rash, hives, swelling of the face, lips, or throat, difficulty breathing — call 911
• Muscle weakness or cramping that is severe (possible sign of significant hypokalaemia)

Key Drug Interactions — Oral Salbutamol

• Beta-blockers (atenolol, metoprolol, propranolol, bisoprolol — commonly prescribed for hypertension and heart conditions in Canada): Non-selective beta-blockers (propranolol) directly antagonise salbutamol's beta-2 bronchodilator effect — this combination can precipitate severe bronchospasm in asthmatic patients and is contraindicated. Cardioselective beta-blockers (atenolol, metoprolol, bisoprolol) are relatively safer but can still partially antagonise bronchodilation and should be used with caution in asthma. Canadian patients on beta-blockers for cardiac conditions who need bronchodilator therapy should discuss this with their physician
• Diuretics (thiazides, furosemide/Lasix): Additive hypokalaemia — both salbutamol and diuretics lower serum potassium. Monitor potassium levels; consider potassium supplementation if levels fall
• Digoxin: Salbutamol-induced hypokalaemia potentiates digoxin toxicity. Serum potassium and digoxin levels require close monitoring in patients taking both
• MAO inhibitors and tricyclic antidepressants: May potentiate the cardiovascular effects of salbutamol — use with caution; enhanced tachycardia and blood pressure effects
• Other sympathomimetic agents: Additive cardiovascular effects — avoid combination with other beta-agonists, decongestants (pseudoephedrine, phenylephrine), or other adrenergic medications unless specifically indicated by physician
• Xanthines (theophylline, aminophylline): Additive hypokalaemia; additive cardiovascular stimulation. Monitor potassium and cardiovascular parameters when combining
• Oxytocin (in obstetric use): Salbutamol can potentially antagonise the uterotonic effect of oxytocin — relevant only in specific obstetric settings

Special Populations — Canadian Considerations

Pregnancy: Salbutamol is generally considered acceptable during pregnancy when clinically indicated — the risk of untreated asthma (reduced oxygen delivery to the fetus during bronchospasm) substantially outweighs the theoretical risks of therapeutic salbutamol exposure. However, oral salbutamol produces higher systemic concentrations than inhaled therapy — inhaled salbutamol is strongly preferred during pregnancy. Intravenous salbutamol is used in obstetric practice for tocolysis (stopping premature labour) in Canada — oral tablets at standard bronchodilator doses are a completely different context. Discuss with your Canadian obstetrician if you are pregnant and require bronchodilator therapy.

Breastfeeding: Salbutamol is excreted in breast milk in small amounts. At standard inhaled doses, the amount in breast milk is clinically negligible. With oral tablets (higher systemic concentrations), slightly more salbutamol may reach breast milk — consult your physician. The inhaled route is preferred during breastfeeding.

Elderly Canadians: Start at the lowest dose (2mg three times daily) and titrate cautiously. Elderly patients are more susceptible to cardiovascular side effects of beta-2 agonism (tachycardia, arrhythmias), more likely to be taking interacting medications (digoxin, diuretics, beta-blockers for hypertension), and may have reduced renal clearance affecting drug accumulation.

Diabetes: Oral salbutamol can cause clinically significant blood glucose elevation through hepatic glycogenolysis and reduced peripheral glucose uptake. Canadian diabetic patients on oral salbutamol should monitor blood glucose more closely during initiation and dose changes, and discuss potential insulin or oral hypoglycaemic dose adjustments with their physician.

Delivery to All Canadian Provinces and Territories

drugs-canada.com ships Ventolin Tablets discreetly to all Canadian provinces and territories. Standard delivery: 4–9 business days.

Ontario (Toronto, Ottawa, Hamilton, London, Brampton, Mississauga, Kitchener-Waterloo) — Quebec (Montreal, Quebec City, Laval, Gatineau, Sherbrooke) — British Columbia (Vancouver, Surrey, Burnaby, Victoria, Kelowna, Abbotsford) — Alberta (Calgary, Edmonton, Red Deer, Lethbridge) — Manitoba (Winnipeg, Brandon) — Saskatchewan (Saskatoon, Regina) — Nova Scotia (Halifax, Sydney) — New Brunswick (Moncton, Saint John, Fredericton) — Newfoundland and Labrador (St. John's, Corner Brook) — Prince Edward Island (Charlottetown) — Northwest Territories (Yellowknife) — Yukon (Whitehorse) — Nunavut (Iqaluit).

All orders are dispatched in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

Frequently Asked Questions — Ventolin Tablets in Canada

Why would my Canadian doctor prescribe salbutamol tablets instead of an inhaler? The inhaled Ventolin inhaler is the strongly preferred form of salbutamol for most Canadian patients because it delivers the drug directly to the airways, works faster (5–15 minutes vs 30–60 minutes for tablets), and causes significantly fewer systemic side effects at effective bronchodilator doses. Your Canadian physician may prescribe tablets if: you are a young child who cannot yet coordinate inhaler technique even with a spacer/face mask device; you have specific physical limitations preventing effective inhaler use; or a specific clinical situation requires systemic bronchodilator therapy. If you have been prescribed tablets but can use an inhaler, discuss with your physician whether switching to inhaled therapy would be appropriate for you.

Can I use Ventolin tablets for an acute asthma attack? No — Ventolin tablets are not appropriate for acute asthma attacks. The onset of action of oral salbutamol is 30 to 60 minutes — far too slow to be useful in an acute attack where rapid bronchodilation is needed within minutes. If you experience an acute asthma attack and only have tablets available (not your inhaler), seek emergency medical care immediately — do not rely on tablets for acute attack management. Every Canadian asthma patient should carry a salbutamol inhaler (Ventolin or equivalent) at all times specifically for acute relief.

Are there more side effects with salbutamol tablets than with the inhaler? Yes — oral salbutamol tablets cause significantly more pronounced systemic side effects than the inhaler, primarily because they produce much higher systemic drug concentrations. Tremor, tachycardia, palpitations, nervousness, and hypokalaemia are all more frequent and more pronounced with oral tablets than with standard inhaled doses. This is one of the primary reasons Canadian asthma guidelines strongly prefer the inhaled route — the inhaler achieves effective bronchodilation at lung doses far lower than the systemic oral dose, minimising systemic exposure and side effects.

My child is too young to use an inhaler — is oral salbutamol appropriate? Oral salbutamol is one option for young children who cannot use an inhaler effectively. However, Canadian paediatric asthma guidelines strongly recommend attempting nebulised or spacer-delivered inhaled therapy first — even for very young children. A face-mask spacer (such as AeroChamber Plus with an appropriately sized mask) allows infants and toddlers to receive inhaled salbutamol without requiring coordination. If your child's Canadian physician has recommended oral tablets, this decision reflects their assessment of your child's specific situation. As children grow, transitioning to inhaled therapy (spacer/mask, then mouthpiece spacer) is the goal.

How long does delivery to Canada take? Standard delivery to all Canadian provinces and territories takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

All information on this page is for general informational purposes only and does not constitute medical advice. Ventolin Tablets (salbutamol) are a Schedule F prescription medicine in Canada — a valid prescription from a licensed Canadian healthcare provider is required. Ventolin tablets are not appropriate for acute asthma attacks — if you are experiencing acute breathing difficulty, seek emergency medical care immediately. Always consult a qualified Canadian physician, nurse practitioner, or pharmacist before starting any respiratory medication.